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Case report
Rapidly progressive obstructive jaundice due
to Congo red negative amyloidosis
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Hepatic involvement in amyloidosis is common but obstructive jaundice is a very
rare complication. Occasional patients with AL amyloidosis develop obstructive
jaundice as a consequence of severe intrahepatic cholestasis, but review of
the English literature reveals only 23 such cases. We report a further case of
obstructive jaundice due to amyloidosis in which the diagnosis was particularly
difficult to establish because the amyloid material was Congo red negative.
CASE REPORT. A 44-year -old previously healthy plumber was admitted to
hospital with a three month history of progressive jaundice, pale stools, dark
urine and itch. He complained of malaise and abdominal discomfort and had lost
14 lbs in weight. His alcohol intake was 18 units per week and he had no
particular risk factors for viral hepatitis. His only medication was oxytetracycline
250mg twice daily for acne rosacea, which he had taken for five years.
Examination revealed deep jaundice. There were no stigmata of chronic liver
disease. The liver was enlarged to 4cm below the costal margin, firm, smooth
and non-tender. The kidneys and spleen were not palpable. There was no
oedema, no peripheral neuropathy and no evidence of cardiac failure. He did not
have macroglossia or bruising. Urinalysis revealed glycosuria but no proteinuria.
Serum bilirubin was 315 pmol/l (usual range 3-18), alkaline phosphatase 441
U/I (35-120), gamma glutamyl transferase 1025 U/l (7-46) and aspartate
transaminase initially 84 U/I (10-40). The prothrombin time was prolonged
to 25-5 seconds (13-17), and serum creatinine was 151 pmol/l (40-110).
Routine screening tests including plasma glucose were normal. The sediment-
ation rate was 54mm/hour, full blood count was normal and antinuclear
antibody, anti -smooth muscleoranti -mitochondrial antibodieswere not detected
in serum. Serological tests for hepatitis A and B, cytomegalovirus, Epstein-
Barr virus, leptospira and toxoplasma were all negative. Serum IgG was raised,
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19-9 g/l (5-16) but there was no reduction in the levels of the other immuno-
globulins to suggest an immune paresis. An IgG paraprotein of 15 g/1 was
identified on electrophoresis ofstored serum. Chest X -ray and electrocardiogram
were within normal limits.
Ultrasound scan failed to identify any abnormality except thickening of the gall-
bladder. Computerised tomography confirmed hepatomegaly with minimal
reduction in liver attenuation values; the spleen and pancreas appeared normal.
After correction of the prothrombin time with fresh frozen plasma, percutaneous
transhepatic cholangiography was attempted to exclude biliary obstruction. The
procedure was technically difficult and three passes were made before the biliary
tree was entered. There was no biliary dilatation but filling ofthe duodenum could
not be demonstrated and an ampullary lesion was suspected. The procedure was
complicated by abdominal pain and a fall in haemoglobin of 5g/dl. Endoscopic
retrograde cannulation of the pancreatic duct was therefore attempted but was
unsuccessful due to distortion of the duodenum by extrinsic compression. At
laparotomy the liver was found to be enlarged, but there was no evidence of
extrahepatic biliary obstruction. A retroperitoneal haematoma was evacuated and
a wedge liver biopsy performed. Postoperatively acute renal failure developed,
characterised by oliguria and rapidly rising serum creatinine to greater than 500
pmol/l. Haemodialysis was complicated by hypotension. Serum bilirubin reached
600 pmol/l. The patient lost consciousness and required artificial ventilation but
despite these measures died 32 days after admission to hospital.
Light microscopy of the operative liver biopsy (Fig 1) confirmed the presence of
marked cholestasis, with slight bile duct proliferation. The hepatic architecture
Fig 1. Liver. The architecture is disrupted and the hepatocytes compressed by amorphous material.
(Masson trichrome x 100).
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was grossly distorted by bands of fibrous tissue but there was no regenerative
activity to establish a diagnosis of cirrhosis. The sinusoids and hepatocytes were
compressed and the appearances were suggestive of amyloid, but Congo red
staining was negative on several occasions. It was felt that extrahepatic biliary
obstruction or sclerosing cholangitis could not definitely be excluded on the basis
of this wedge biopsy.
At the subsequent necropsy the body was deeply jaundiced. The liver was
enlarged, weighing 3150g. The liver capsule was intact, apart from the sutured
biopsy site. It had a finely nodular external and cut surface. The extrahepatic
biliary tree was patent, with noevidence ofobstruction ordilatation. The pancreas
appeared macroscopically normal, with no evidence of tumour. The ampulla was
normal. The remains of a retroperitoneal haematoma was present behind the
duodenum in close relation to the lower end ofthe common bile duct. No definite
bleeding point could be identified and there was no perforation of the common
bile duct or duodenum. The sDleen was enlaraed. weiahina 319 a. It had a sliahtlv
firm consistency on cut section.
Histologically the postmortem
liver was similar to the biopsy.
Sections from both were stained
repeatedly with Congo red, Thio-
flavine T and Sirius red but results
were consistently negative.
Immunoperoxidase staining of
liver for AA amyloid was also
negative. Stains for kappa and
lambda light chains showed no
evidence of light chain restriction.
Electron microscopyofthebiopsy
and postmortem liver showed
similar features (Fig 2). Therewas
widespread deposition of extra-
cellular fibrillar material in the
perisinusoidal space of Disse and
between hepatocytes. Thismater-
ial was composed of aggregates
of non-branching fibrils, 9 nm in
diameter in a felt like meshwork.
The appearances supported a
diagnosis of Congo red negative
amyloidosis.
Fig 2. Electron micrograph of liver showing amyloid
material lining thespace of Disse. (Uranyl acetate, lead
citrate x 3500).
Inset: High power of the amyloid fibrils ( x 105).
Histological examination showed infiltration of multiple organs with amyloid
material. The heart, thyroid gland, adrenal glands, pancreas, spleen and kidneys
were all involved. The appearances of the kidneys on light microscopy were
typical (Fig 3). Amyloid material was noted around renal arterioles, in the
interstitium and to a lesser extent, focal glomerular infiltration. The renal tubules
showed a significant degree of flattening of the tubular epithelium with tubular
dilatation indicative of acute tubular necrosis. In the thyroid gland there was
striking separation of the follicles by the amyloid material. Immunoperoxidase
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Fig 3. Kidney. There is interstitial deposition of amorphous material which electron microscopic
examination confirmed to be amyloid. The appearances in several other organs were similar (see text).
(Haematoxylin and eosin x 250).
staining for calcitonin was negative as were the conventional light microscopical
stains for amyloid. Involvement ofthe adrenal glands was confined to the medulla
with compression atrophy of the medullary parenchymal cells and a notable
sparing of the adrenal cortex. Within the pancreas the ducts and blood vessels
were infiltrated by same material. The splenic arterioles were involved along with
diffuse infiltration of the splenic red pulp. The heart showed diffuse interstitial
infiltration.
DISCUSSION
Although the liver is frequently involved in amyloidosis, obstructivejaundice due
to severe intrahepatic cholestasis is a very rare complication. In this case, the
cause of the jaundice only became apparent when electron microscopy of liver
tissue revealed the ultrastructural appearance of amyloidosis. Oxytetracycline
is recognised to cause microvesicular fatty metamorphosis. This complication
usually occurs within afew daysofstarting large doses administered parenterally. I
It isunlikely that oxytetracycline wasthe causeofliverdysfunction and withdrawal
of the drug on admission to hospital was not associated with any improvement.
There was no evidence at autopsy of sclerosing cholangitis, cholangiocarcinoma
or drug-induced hepatic injury which had earlier been considered in the differ-
ential diagnosis.
There was no clinical or pathological evidence of chronic disease which might
have given rise to secondary amyloidosis, and the absence of clinical features of
multiple myeloma and the presence of an IgG paraprotein indicate that this was
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a case of primary or immunocyte-related (AL) amyloidosis.2 In these cases
the amyloid protein is derived from light chain fragments of immunoglobulins.
Primary AL amyloidosis involves the liver in 65-70% of cases,3 but significant
liver dysfunction is very rare and death isusuallydue torenal insufficiency, cardiac
failure or sudden cardiac death.
A recognised subgroup of patients with AL amyloidosis do develop severe intra-
hepatic cholestasis. Reviewoftheliterature reveals23 previouscases.4,5 Including
this case, there is a majority of males (15:9) and the age range is 29-80 years.
The serum bilirubin at presentation was in excess of 300 pmol/l in only six out
of the twenty-four cases and a monoclonal paraprotein band was detected in
the serum in eight of twelve cases where it was sought. Multiple myeloma was
diagnosed in only one case6 and in one case the M band was due to free lambda
light chains. Death was due to renal failure in seventeen of twenty cases where
thecause wasrecorded. Median survival wasonly 12 weeks (range 3 -52 weeks).
The cause of cholestasis in this subgroup is unclear. It has been postulated that
the pattern ofamyloid deposition in these cases interferes with the passage of bile
from canaliculi and/or small intrahepatic bile ducts to septal bile ducts.7 The
microscopic findings in our case would support this hypothesis.
This case also illustrates the difficulty which has frequently been encountered in
diagnosis. Ultrasound and CT scans are typically non-diagnostic. The negative
staining with Congo red and other amyloid stains increased our difficulty. Melato
et al noted variable affinity for Congo red in their series of cases of hepatic
amyloidosis.8 We confirm that conventional stains for amyloid may be falsely
negative and that electron microscopy is a more sensitive diagnostic technique.
The presence of a paraprotein band in a jaundiced patient with no stigmata of
chronic liver disease and no radiological evidence of biliary tract obstruction
should raise the possibility of hepatic AL amyloidosis. Percutaneous liver biopsy
is the procedureof choice to obtain a histological diagnosis.9 There is some added
risk of bleeding complications with invasive procedures, as illustrated by this
case, even when the prothrombin time has been corrected, probably as a result of
involvement of blood vessels by amyloid.
There is no established effective therapy for primary hepatic amyloidosis. Several
authors have reported regression of hepatomegaly following treatment with a
combination of melphalan and prednisone.6 10,11,12,13 In one case amyloid was
present in a liver biopsy specimen before treatment and absent aftertreatment.10
Colchicine and dimethylsulphoxide have also been tried'4 but no treatment has
been reported to be of benefit in cases of severe cholestasis.5 The prognosis in
such cases is very poor.
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